Online inquiry

IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6539MR)

This product GTTS-WQ6539MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Uveitis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6539MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7529MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ501MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ7208MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ277MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ727MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ6255MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ9281MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ5492MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP 6038
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW